Methylation profiling

Dataset Information

0

Methotrexate treatment of newly diagnosed RA patients is associated with DNA methylation differences at genes relevant for disease pathogenesis and pharmacological action


ABSTRACT: Background: Methotrexate (MTX) is the first line treatment of rheumatoid arthritis (RA), and methylation changes in bulk T cells have been reported after treatment with MTX. We have investigated cell-type specific DNA methylation changes across the genome in naïve and memory CD4+ T cells before and after MTX treatment of RA patients. DNA methylation profiles of newly diagnosed RA patients (N=9) were assessed by reduced representation bisulfite sequencing. Results: We found that MTX treatment significantly influenced DNA methylation levels at multiple CpG sites in both cell populations. Interestingly, we identified differentially methylated sites annotated to two genes; TRIM15 and SORC2, previously reported to predict treatment outcome in RA patients when measured in bulk T cells. Furthermore, several of the genes, including STAT3, annotated to the significant CpG sites are relevant for RA susceptibility or the action of MTX. Conclusion: We detected CpG sites that were associated with MTX treatment in CD4+ naïve and memory T cells isolated from RA patients. Several of these sites overlap genetic regions previously associated with RA risk and MTX treatment outcome.

ORGANISM(S): Homo sapiens

PROVIDER: GSE188509 | GEO | 2021/11/11

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2020-02-07 | GSE135770 | GEO
2021-02-07 | E-MTAB-10159 | biostudies-arrayexpress
2024-10-02 | GSE271209 | GEO
2017-06-09 | GSE87095 | GEO
2024-03-22 | GSE42842 | GEO
2024-06-16 | PXD016870 | Pride
2023-06-28 | GSE229449 | GEO
2017-07-29 | GSE71841 | GEO
2014-01-29 | GSE35455 | GEO
2021-10-20 | ST001949 | MetabolomicsWorkbench